RT Journal Article
SR Electronic
T1 Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1675
OP 1681
DO 10.1136/ijgc-2023-004454
VO 33
IS 11
A1 Mahdi, Haider
A1 Ray-Coquard, Isabelle
A1 Lorusso, Domenica
A1 Mirza, Mansoor Raza
A1 Monk, Bradley J
A1 Slomovitz, Brian
YR 2023
UL http://ijgc.bmj.com/content/33/11/1675.abstract
AB Endometrial cancer is the most common gynecologic malignancy in developed countries, with increasing incidence and mortality rates worldwide. While most cases are successfully treated with surgery, first-line treatment options for metastatic or recurrent endometrial cancer involve significant toxicities. Imprecise classification of heterogeneous subgroups further complicates treatment decisions and interpretation of clinical trial results. Recent advances in molecular classification are guiding treatment decisions for metastatic or recurrent endometrial cancers. Integrating molecular characteristics with traditional clinicopathology can both reduce overtreatment or undertreatment and help guide the appropriate choice of therapies and effective design of future studies. Here we discuss the treatment of metastatic or recurrent low-grade endometrioid adenocarcinoma of the uterine corpus, which is distinct from high-grade tumors histologically, molecularly, and in treatment response.